Frost & Sullivan Independent Equity Research
Cellect. On track with its strategic plans; successfully completed proof of concept for ApoTainerTM; sufficient cash to support clinical and preclinical trials; price target unchanged
![logo_cellect-biotech logo_cellect-biotech](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/logo_cellect-biotech-nx7oenqvj2y33m2uhxiuo5wv2s7xme8mc1ykanhgzk.jpg)
Company: Cellect Biotechnology Ltd.
Sector: Biotechnology
Report type: Annual 2017, Q1-2018 and 12 mos. Since Initiation Updates
Published on: 30 May, 2018